{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:00:17Z","timestamp":1761181217824,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jbspin.2019.10.004","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T12:45:50Z","timestamp":1571921150000},"page":"137-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients"],"prefix":"10.1016","volume":"87","author":[{"given":"Bruno","family":"Fautrel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Belhassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Hudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Woronoff-Lemsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Levy-Bachelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Van Ganse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2019.10.004_bib0055","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.10.004_bib0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jbspin.2006.06.011","article-title":"TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease","volume":"74","author":"Brocq","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2019.10.004_bib0065","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jbspin.2014.02.014","article-title":"Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice","volume":"81","author":"Frazier-Mironer","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2019.10.004_bib0070","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France. SNIIRAM and EGB: Powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jbspin.2019.10.004_bib0075","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","article-title":"Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence","volume":"36","author":"Dalen","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2019.10.004_bib0080","first-page":"423","article-title":"Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study","volume":"35","author":"Calvo-Alen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2019.10.004_bib0085","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2019.10.004_bib0090","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2147\/PPA.S110147","article-title":"Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan","volume":"10","author":"Mahlich","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jbspin.2019.10.004_bib0095","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s10067-017-3805-4","article-title":"Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative","volume":"36","author":"Ahluwalia","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2019.10.004_bib0100","first-page":"1737","article-title":"Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis","volume":"35","author":"Agarwal","year":"2008","journal-title":"J Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19301514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19301514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:25:36Z","timestamp":1761150336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X19301514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1297319X19301514"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.10.004","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}]}}